Nab-paclitaxel in the treatment of breast cancer: clinical trial data and first-hand experience

Abstract

The article considers the place of nab-paclitaxel in the treatment of metastatic breast cancer. A number of studies have shown high efficacy and acceptable toxicity in comparison with traditional taxanes. The low frequency of hypersensitivity reactions allows the use of nab-paclitaxel in patients who had reactions with the introduction of traditional taxanes and in the presence of contraindications to corticosteroids premedication. The absence of cross-resistance makes possible to prescribe nabpaclitaxel in patients who had progression on treatment with paclitaxel and docetaxel. The cases of effective use of the drug from our own practice are presented.